Figure 3
From: Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma
Pembrolizumab drug and anti-drug antibody (ADA) levels in 3 patients with results suggestive of a neutralising ADA. 3/41 patients (7%) with results suggestive of a neutralising ADA are shown. All 3 patients had falling pembrolizumab drug levels and rising ADA between Cycle 2 (T1) and last available time-point (T2; Median Cycle 7 or 21 weeks IQR Cycle 4-13).
